Abstract: The present disclosure relates to techniques for segmenting tumors with positron emission tomography (PET) using deep convolutional neural networks for image and lesion metabolism analysis.
Type:
Grant
Filed:
September 13, 2021
Date of Patent:
October 15, 2024
Assignee:
GENENTECH, INC.
Inventors:
Nils Gustav Thomas Bengtsson, Richard Alan Duray Carano, Alexander James Stephen Champion de Crespigny, Jill Osborn Fredrickson, Mohamed Skander Jemaa
Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma “DLBCL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an anti-CD20 antibody, chemotherapy and a corticosteroid.
Type:
Application
Filed:
August 2, 2022
Publication date:
October 10, 2024
Applicants:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Jamie Harue HIRATA, Calvin Ka Yin LEE, Huan JIN, Lijia WANG, Jiaheng QIU, Qingxiang YAN
Abstract: Described herein are sulfonimidamide compounds, solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing. Further described herein are methods of treating a disorder in a subject in need thereof using said compounds, solvates, tautomers, or pharmaceutically acceptable salts thereof, such as NLRP3-mediated disorders.
Type:
Application
Filed:
July 15, 2022
Publication date:
October 10, 2024
Applicant:
Genentech, Inc.
Inventors:
Kwong Wah LAI, Christian NILEWSKI, Richard M. PASTOR, Craig STIVALA
Abstract: This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
Type:
Grant
Filed:
November 21, 2022
Date of Patent:
October 8, 2024
Assignee:
GENENTECH, INC.
Inventors:
Jason Robert Zbieg, Russell Tyler Smith, Paul Powell Beroza, Vishal Anil Verma, Bing-Yan Zhu, Ramsay Beveridge, Lisa Marie Barton, Bryan Ka Ip Chan, Curtis Colwell, Samir Bouayad-Gervais, Anwesha Dey, Marie Anne Evangelista
Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
Abstract: Provided herein are anti-?v?8 antibodies or antigen-binding portions thereof and methods of making and using the same. Further provided are methods of treating cancer with an anti-?v?8 and a PD-1 axis antagonist.
Type:
Application
Filed:
March 29, 2024
Publication date:
October 3, 2024
Applicant:
Genentech, Inc.
Inventors:
WeiYu LIN, Kelly Michele LOYET, Matthieu MASUREEL, Minh THAI, Shannon Jennifer TURLEY, Tulika TYAGI, Yan WU, Jianhuan ZHANG, Alessandra CASTIGLIONI, Cecilia Pui Chi CHIU
Abstract: The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.
Abstract: The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.
Type:
Application
Filed:
March 19, 2024
Publication date:
October 3, 2024
Applicant:
Genentech, Inc.
Inventors:
Minhong Yan, Gu Zhang, Nicholas John Agard, Danielle Marie DiCara, Philip E. Hass, Julie Q. Hang, Erin L. Christensen, Robert Paul Morse, Sarah Sanowar, Vittal Shivva
Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
Type:
Grant
Filed:
March 30, 2021
Date of Patent:
October 1, 2024
Assignee:
Genentech, Inc.
Inventors:
Martin Gawlitzek, Shun Luo, Christina Teresa Bevilacqua
Abstract: Provided herein are solid forms, salts, and formulations of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.
Type:
Application
Filed:
August 25, 2023
Publication date:
September 26, 2024
Applicants:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Cheol Keun CHUNG, Jie XU, Hans IDING, Kyle CLAGG, Michael DALZIEL, Alec FETTES, Francis GOSSELIN, Ngiap-Kie LIM, Andrew MCCLORY, Haiming ZHANG, Paroma CHAKRAVARTY, Karthik NAGAPUDI, Sarah ROBINSON
Abstract: The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.
Type:
Grant
Filed:
March 26, 2021
Date of Patent:
September 24, 2024
Assignee:
GENENTECH, INC.
Inventors:
Michael Wilson Laird, Shahram Misaghi, Amy Shen, Anthony Tomlinson, Inn Huam Yuk
Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
Type:
Grant
Filed:
December 16, 2021
Date of Patent:
September 24, 2024
Assignee:
GENENTECH, INC.
Inventors:
Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton
Abstract: The invention provides anti-hypusine antibodies and their use in detecting and isolating polypeptides containing hypusine and/or deoxyhypusine, as well as compositions and kits comprising the anti-hypusine antibodies.
Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
Type:
Grant
Filed:
March 31, 2023
Date of Patent:
September 24, 2024
Assignee:
Genentech, Inc.
Inventors:
Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
Type:
Application
Filed:
December 21, 2023
Publication date:
September 19, 2024
Applicant:
Genentech, Inc.
Inventors:
Yvonne CHEN, Mark DENNIS, David DORNAN, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
Abstract: The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
Type:
Application
Filed:
November 13, 2023
Publication date:
September 19, 2024
Applicant:
Genentech, Inc.
Inventors:
Masaru Ken SHIRATORI, Robert David KISS, Hardayal PRASHAD, Raquel IVERSON, Justin BOURRET, Michael KIM, Salim CHARANIYA
Abstract: The subject matter described herein is directed to methods of preparing certain antibody-drug conjugates (ADCs) wherein the antibody is linked to the drug through a linker, wherein the drug contains a heteroaryl group having a secondary nitrogen, and the linker is attached to the drug via the secondary nitrogen. The resulting conjugates are useful in treating various diseases and conditions.
Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.
Type:
Application
Filed:
May 14, 2024
Publication date:
September 12, 2024
Applicant:
Genentech, Inc.
Inventors:
Marie EVANGELISTA, Mark Andrew MERCHANT, Jennifer Lee SCHUTZMAN, Ting-Kun Mark LIN, Stephanie Royer JOO, Sandhya Vinayak MANDLEKAR, Stuart G. LUTZKER
Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.